Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 5/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | APAF1 | O14727 | 2/20 | 0.32 |
| ▸ | CASP3 | P42574 | 2/20 | 0.32 |
| ▸ | CASP9 | P55211 | 2/20 | 0.32 |
| ▸ | CYCS | P99999 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3702465 | 0.90 | PSEN1 (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3713311 | 0.89 | PSEN1 (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3696901 | 0.87 | APAF1 (0.38) | ALDH1A1USP2APAF1CASP3CASP9 | |
| SCHEMBL9099915 | 0.86 | PSEN1 (0.34) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3693763 | 0.85 | TBXAS1 (0.40) | TBXAS1ALDH1A1USP2 | |
| SCHEMBL3709359 | 0.84 | APAF1 (0.36) | USP2APAF1CASP3CASP9CYCS | |
| SCHEMBL3705123 | 0.84 | GPBAR1 (0.37) | ALDH1A1APAF1CASP3CASP9CYCS | |
| SCHEMBL3695657 | 0.82 | GLA (0.40) | ALDH1A1APAF1CASP3CASP9CYCS | |
| SCHEMBL3704033 | 0.82 | APAF1 (0.36) | ALDH1A1APAF1CASP3CASP9CYCS | |
| SCHEMBL3702398 | 0.82 | APAF1 (0.35) | ALDH1A1USP2APAF1CASP3CASP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040701-B2 | Apaf-1 inhibitor compounds | LABORATORIOS SALVAT, S.A. (ES) | 2015-05-26 | — | — | US | disclosed |
| US-20120122868-A1 | APAF-1 INHIBITOR COMPOUNDS | LABORATORIOS SALVAT, S.A. (ES) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122868-A1 | APAF-1 INHIBITOR COMPOUNDS | APAF1, API5, AIFM1 | PSEN1 742/4885PSEN2 1541/4885APH1B 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.